Syneos Health exec jumps ship to Canadian CRO Altasciences

Canada and Quebec flags
The Canadian CRO's hire will be focused on helping clients in the earlier stages of devlepoment (Wikimedia Commons)

Biopharma and CRO veteran Beatrice Setnik, Ph.D., has become the new chief scientific officer at Canadian clinical research firm Altasciences.

Setnik, also a Pfizer alum, joins the company from Syneos Health (created by the merger of inVentiv Health and INC Research) where she spent five years, most recently as its VP of scientific and medical affairs.

Altasciences says that as CSO she will go about “supporting our internal and external clients with her expertise in all areas relating to early drug development.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We are extremely fortunate to add a candidate of such caliber and talent to our team. We look forward to Dr. Setnik’s contributions which will reinforce Altasciences’ extensive offerings in early phase preclinical and clinical research,” said Chris Perkin, CEO at Altasciences.

Last year, the midsized CRO penned a new deal that saw it snap up the preclinical testing business of SNBL USA.

The buyout added “comprehensive preclinical safety testing services” to Altasciences’ current clinical and bioanalytical offerings, according to its PR.

Algorithme Pharma, Vince & Associates Clinical Research and Algorithme Pharma USA operate under the Altasciences umbrella. Combined, they boast more than 600 beds for phase I/II studies.

Altasciences, which was acquired by Audax Group in June 2017, bought Vince & Associates in 2013. That deal was followed by the launch of Algorithme Pharma USA the next year.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.